Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Egypt. J. Exp. Biol. (Zoo.). 2015; 11(1): 15-21


AMELIORATING ROLE OF JAMBOLAN OF CAPECITABINE INDUCED TESTICULAR DAMAGE OF RATS

Heba A. El-Ghawet, Abdelalim A. Gadallah.




Abstract

Capecitabine (Xeloda, Roche) is a pro- anticancer drug, that is enzymatically converted to 5-fluorouracil in the body. The present work aimed to evaluate the ameliorated role of the jambolan fruit-extract against testicular damage induced by capecitabine. Twenty male Wistar albino rats (Rattus norvegicus) weighing approximately 120 g were used during experimentation. Animals were divided into four groups; control (saline-treated), Jambolan-treatment (400 mg/kg of fruit extract), capicitabine-treatment (40 mg /Kg BW for 30 days), and capicitabine and jambolan-treatment. Daily oral treatments were carried out for 30 days. At the end of experimentation period, the animals were sacrificed and their testis were incised and processed for histopathological investigation, comet and flow cytometric analysis for apoptosis. The present findings revealed that the drug-treatment possessed dramatic testicular damage in the form of focal disorganization of the seminiferous tubules with almost missing of sperm, comparatively decreased spermatogenic cells, sloughing and degeneration of spermatogenic cells and interstitial oedematous lesions. Flow cytometric analysis showed apparent increase of apoptic M1 spermatogenic and ovarian cells. Comet assay revealed apparent increase of detached spermatogenic cells. Jambolan-treatment ameliorated the pathological picture and decreased the incidence of apoptosis. Finally, the authors concluded that the jambolan-treatment with its higher content of antioxidants resolute the toxicological aspects of the anticancer drugs.

Key words: Capecitabine, Jambolan, testicular damage, amelioration effect






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.